Literature DB >> 23900779

Improved survival modeling in cancer research using a reduced piecewise exponential approach.

Gang Han1, Michael J Schell, Jongphil Kim.   

Abstract

Statistical models for survival data are typically nonparametric, for example, the Kaplan-Meier curve. Parametric survival modeling, such as exponential modeling, however, can reveal additional insights and be more efficient than nonparametric alternatives. A major constraint of the existing exponential models is the lack of flexibility due to distribution assumptions. A flexible and parsimonious piecewise exponential model is presented to best use the exponential models for arbitrary survival data. This model identifies shifts in the failure rate over time based on an exact likelihood ratio test, a backward elimination procedure, and an optional presumed order restriction on the hazard rate. Such modeling provides a descriptive tool in understanding the patient survival in addition to the Kaplan-Meier curve. This approach is compared with alternative survival models in simulation examples and illustrated in clinical studies.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  exponential survival; median survival; nonsmall cell lung cancer; survival analysis

Mesh:

Year:  2013        PMID: 23900779      PMCID: PMC3913785          DOI: 10.1002/sim.5915

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  19 in total

1.  Maximum likelihood methods for cure rate models with missing covariates.

Authors:  M H Chen; J G Ibrahim
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

2.  Phase specific analysis of herpes zoster associated pain data: a new statistical approach.

Authors:  R B Arani; S J Soong; H L Weiss; M J Wood; P A Fiddian; J W Gnann; R Whitley
Journal:  Stat Med       Date:  2001-08-30       Impact factor: 2.373

3.  Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution.

Authors:  Christopher Cox; Haitao Chu; Michael F Schneider; Alvaro Muñoz
Journal:  Stat Med       Date:  2007-10-15       Impact factor: 2.373

Review 4.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

5.  Covariance analysis of censored survival data.

Authors:  N Breslow
Journal:  Biometrics       Date:  1974-03       Impact factor: 2.571

6.  The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Authors:  Lesley Seymour; S Percy Ivy; Daniel Sargent; David Spriggs; Laurence Baker; Larry Rubinstein; Mark J Ratain; Michael Le Blanc; David Stewart; John Crowley; Susan Groshen; Jeffrey S Humphrey; Pamela West; Donald Berry
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

7.  Concurrent prediction of hospital mortality and length of stay from risk factors on admission.

Authors:  David E Clark; Louise M Ryan
Journal:  Health Serv Res       Date:  2002-06       Impact factor: 3.402

8.  Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test.

Authors:  Gang Han; Michael J Schell; Jongphil Kim
Journal:  Stat Biopharm Res       Date:  2012-10-01       Impact factor: 1.452

9.  Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

Authors:  George R Simon; Martine Extermann; Alberto Chiappori; Charles C Williams; Mubeena Begum; Rachna Kapoor; Eric B Haura; Roohi Ismail-Khan; Michael J Schell; Scott J Antonia; Gerold Bepler
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

10.  Connexin 43 is a potential prognostic biomarker for ewing sarcoma/primitive neuroectodermal tumor.

Authors:  Marilyn M Bui; Gang Han; Geza Acs; Damon Reed; Ricardo J Gonzalez; T L Pasha; Paul J Zhang
Journal:  Sarcoma       Date:  2011-05-08
View more
  9 in total

1.  Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.

Authors:  So Young Ji; Jongjin Lee; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Jin Wook Kim; Yong Hwy Kim; Tae Min Kim; Seung Hong Choi; Sung-Hye Park; Yongdai Kim; Chul-Kee Park
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

2.  Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival.

Authors:  Bart Barlogie; Vanessa Bolejack; Michael Schell; John Crowley
Journal:  Ann Hematol       Date:  2010-12-14       Impact factor: 3.673

3.  Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival.

Authors:  Hye In Lee; Jongjin Lee; Joo Ho Lee; Hong-Gyun Wu; Jin Ho Kim; Yongdai Kim; Keun-Yong Eom
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2022-09-29       Impact factor: 8.961

4.  Testing violations of the exponential assumption in cancer clinical trials with survival endpoints.

Authors:  Gang Han; Michael J Schell; Heping Zhang; Daniel Zelterman; Lajos Pusztai; Kerin Adelson; Christos Hatzis
Journal:  Biometrics       Date:  2016-09-26       Impact factor: 2.571

5.  Bridged parametric survival models: General paradigm and speed improvements.

Authors:  Bruce J Swihart; Dipankar Bandyopadhyay
Journal:  Comput Methods Programs Biomed       Date:  2021-04-28       Impact factor: 7.027

6.  Identifying change points in a covariate effect on time-to-event analysis with reduced isotonic regression.

Authors:  Yong Ma; Yinglei Lai; John M Lachin
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

7.  End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.

Authors:  Antje Hoering; Brian Durie; Hongwei Wang; John Crowley
Journal:  Future Oncol       Date:  2017-04-11       Impact factor: 3.404

8.  Lipid-Based Factors: A Promising New Biomarker for Predicting Prognosis and Conditional Survival Probability in Hepatocellular Carcinoma.

Authors:  Ziwei Guo; Jun Liang
Journal:  J Hepatocell Carcinoma       Date:  2022-08-26

9.  Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Authors:  Kerin Adelson; Bhuvaneswari Ramaswamy; Joseph A Sparano; Paul J Christos; John J Wright; George Raptis; Gang Han; Miguel Villalona-Calero; Cynthia X Ma; Dawn Hershman; Joseph Baar; Paula Klein; Tessa Cigler; G Thomas Budd; Yelena Novik; Antoinette R Tan; Susan Tannenbaum; Anupama Goel; Ellis Levine; Charles L Shapiro; Eleni Andreopoulou; Michael Naughton; Kevin Kalinsky; Sam Waxman; Doris Germain
Journal:  NPJ Breast Cancer       Date:  2016-12-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.